American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4003)
  2. Hematologic Malignancies, Division of (3806)
  3. Center for Hematologic Malignancies (3683)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1345)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (989)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1261)
  3. Research Letter (46)
  4. Review (43)
  5. Editorial (35)
  6. Guidelines (14)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4003)
  2. Hematologic Malignancies, Division of (3806)
  3. Center for Hematologic Malignancies (3683)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1345)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (349)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (68)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5175)
  2. Blood Advances (334)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5559)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted sequencing reveals novel gene mutations associated with transformation and early progression in follicular lymphoma
    Meeting Abstract

    Kridel, R.; Chan, F. C.; Mottok, A.; Boyle, M.; Farinha, P.; Tan, K.; Meissner, B.; Bashashati, A.; Ben-Neriah, S.; Gine, E.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Longitudinal (18)f-FDG-PET-CT analysis in newly diagnosed multiple myeloma (NDMM) patients following carfilzomib, lenalidomide, dexamethasone induction and lenalidomide maintenance (CRd-R)
    Meeting Abstract

    Korde, N. S.; Kazandjian, D.; Roschewski, M.; Mailankody, S.; Hultcrantz, M.; Yuan, C. M.; Stetler-Stevenson, M.; Choyke, P.; Hassoun, H.; Lesokhin, A. M.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • The final report of a phase I/II study of panobinostat in combination with ICE (ifosfamide, carboplatin and etoposide) in patients (pts) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL)
    Meeting Abstract

    Hu, B.; Younes, A.; Claret, L.; Feng, L.; Westin, J. R.; Fowler, N.; Neelapu, S.; Hagemeister, F. B.; Rodriguez, M. A.; Samaniego, F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Long-term follow-up of the efficacy and safety of ponatinib in Philadelphia chromosome-positive leukemia patients with the T315I mutation
    Meeting Abstract

    Jabbour, E. J.; Cortes, J. E.; Talpaz, M.; Baccarani, M.; Mauro, M. J.; Hochhaus, A.; Hughes, T. P.; Guilhot, F.; Deininger, M. W.; Shah, N.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • The impact of prior malignancies on second malignancies and survival in MM patients: A population-based study
    Meeting Abstract

    Jonsdottir, G.; Lund, S. H.; Björkholm, M.; Turesson, I.; Wahlin, A.; Hultcrantz, M.; Porwit, A.; Landgren, O.; Kristinsson, S. Y.
    Blood (2016)

    Fulltext@MSK | Save
  • Real-world clinical and economic burden of hematopoietic cell transplantation among a large US commercially insured populationhematopoietic cell transplantation among a large US commercially insured population
    Meeting Abstract

    Josephson, N. C.; Garfin, P. M.; Richhariya, A.; Bonafede, M.; Donna, M.; Cai, Q.; Perales, M.
    Blood (2016)

    Fulltext@MSK | Save
  • Phase I trial of targeted alpha-particle therapy with Actinium-225 ((225)Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Levy, M. Y.; Park, J. H.; Ravandi, F.; Perl, A. E.; Pagel, J. M.; Smith, B. D.; Estey, E. H.; Kantarjian, H.; Cicic, D.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Sustained high rates of complete response and minimal residual disease negativity after 8 cycles of carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R) in patients with high-risk smoldering multiple myeloma: Updated results of clinical and correlative phase 2 study
    Meeting Abstract

    Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • TP53 mutations in AML predict adverse outcome in patients undergoing allogeneic hematopoietic stem cell transplant
    Meeting Abstract

    Getta, B. M.; Ghosh, A.; Coombs, C. C.; Devlin, S.; Arcila, M.; Mohanty, A.; Levine, R. L.; Tallman, M. S.; Jakubowski, A. A.; Giralt, S. A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic stem cell transplant with ablative conditioning is associated with favorable outcomes in patients with mixed phenotype acute leukemia
    Meeting Abstract

    Getta, B. M.; Zheng, J. T.; Tallman, M. S.; Park, J. H.; Stein, E. M.; Roshal, M.; Papadopoulos, E. B.; Kernan, N. A.; Steinherz, P. G.; O'Reilly, R. J.; more...
    Blood (2016)

    Fulltext@MSK | Save